abstract details

The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.

Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis


Burmester GR1, Gordon KB2, Rosenbaum JT3, Arikan D4, Lau WL4, Li P4, Faccin F4, Panaccione R5. Adv Ther. 2020 Jan;37(1):364-380. doi: 10.1007/s12325-019-01145-8. Epub 2019 Nov 20.

Author Information

1 Charité Universitätsmedizin Berlin, Berlin, Germany. gerd.burmester@charite.de.

2 Medical College of Wisconsin, Milwaukee, WI, USA.

3 Oregon Health and Science University and Legacy Devers Eye Institute, Portland, OR, USA.

4 AbbVie, North Chicago, IL, USA.

5 University of Calgary, Calgary, AB, Canada.



The safety profile of adalimumab was previously reported in 23,458 patients across multiple indications. Here we report the long-term safety of adalimumab in adults with plaque psoriasis (Ps), hidradenitis suppurativa (HS), rheumatoid arthritis (RA), ankylosing spondylitis, psoriatic arthritis, non-radiographic axial spondyloarthritis, peripheral spondyloarthritis, Crohn's disease (CD), ulcerative colitis (UC), and non-infectious uveitis (UV).


Safety data from 77 clinical trials were pooled. Safety assessments included adverse events (AEs) and serious AEs (SAEs) that occurred after the first study dose and within 70 days (5 half-lives) after the last study dose.


A total of 29,967 patients were included, representing 56,916 patient-years (PY) of exposure. The most frequently reported SAE of interest was infection (3.7/100 PY) with highest incidences in CD, RA, UV, and UC (3.5/100 PY-6.9/100 PY); serious infections in Ps (1.8/100 PY) and HS (2.8/100 PY) were lower. The observed number of deaths was below what would be expected in an age- and sex-adjusted population for most adalimumab-treated patients (including Ps). Lack of real-life data and limited long-term data (> 5 years) for most patients are limitations of this analysis.


The safety profile of adalimumab was consistent with previous findings and no new safety signals were observed.